Lilly’s Novel Alzheimer’s Disease Drug on Target, Diabetes Drug Gains Approval
Eli Lilly’s experimental Alzheimer’s disease treatment solanezumab is moving forward in separate Phase III trials after clearing a planned analysis by a data monitoring committee.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.